Hikma
Aug 8, 2024 · Hikma launches Clindamycin in 5% Dextrose Injection in the US Press Release, Product 03 September 2024. Hikma is a global pharmaceutical company that manufactures high-quality generic medicines and makes them accessible to people who need them.
Overview - Hikma
Discover our world-class 360° pharmaceutical contract manufacturing (CMO) capabilities across a broad range of oral and non injectable dosage forms, best-in-class production facilities, and excellent quality track record.
Who we are - Hikma
Hikma was founded over 45 years ago with the mission to make high-quality medicines accessible to those who need them. This has been our focus every day since, and now, with new leadership and a refreshed, ambitious strategic focus, we are well placed for our next chapter of growth.
Products - Hikma
California SB 1765 (California Business & Professions Code 119400, 119402) requires pharmaceutical companies to set an annual aggregate limit on certain promotional expenditures provided to a medical or health care professional as defined under the statute.
Products - Hikma
We provide patients across our markets with 760+ high-quality and affordable medicines. We manufacture and bring patients across North America, MENA and Europe a broad range of injectable and oral generics, branded generics, specialty and branded pharmaceutical and compounded products.
Egypt - Hikma
In Egypt, we produce and commercialise medicines from our three manufacturing plants, which specialise in cephalosporins, general formulation, and oncology medicines. In addition, we commercialise the medicines of our pharmaceutical partners who rely on our expertise and knowledge of the market.
Investors - Hikma
Together we’re building a leading global pharmaceutical business. By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns. Explore our strategy.
History - Hikma
Founded 45 years ago by Samih Darwazah, Hikma's purpose has always been to make high-quality medicines accessible to the people who need them. Based on the solid foundation we have built, we will continue to transform the lives of the millions of people we serve.
Hikma Pharmaceuticals: how our three businesses work together …
Jul 31, 2024 · Today, Hikma is the second-largest pharmaceutical company by sales in the region 2, operating across 17 markets with 20 plants in six countries. We have rapidly developed our product portfolio to treat cancer and chronic illnesses, with 60% of our Branded portfolio for chronic conditions.
Hikma acquires Xellia’s differentiated portfolio and enhances ...
Jun 17, 2024 · The acquisition will add eight approved and marketed injectable products to Hikma’s US portfolio and 11 pipeline products. The Xellia commercial portfolio comprises the ready-to-use formulation, Vanco Ready® (vancomycin), launched in …